![](https://www.marketscreener.com/images/twitter_MS_fdnoir.png)
End of day quote
October 18, 2023 06:00:00 PM Eastern Time |
|
5 days change |
Changes on January 1 |
|
14.17 CNY |
-9.97% |
+12.37% |
+72.38% |
This article is reserved for members
Non-members?
free registration
Beijing Shuanglin Pharmaceutical’s anti-hepatitis C drug trial approved; stock price fell 10% |
mt. |
|
Kanghui Pharmaceutical denies speculation that relevant units are involved in the production of weight-loss drugs |
mt. |
|
Beijing Shuanglin Pharmaceutical’s pegylated human granulocyte stimulating factor injection obtained certificate; stock price rose 3% |
mt. |
|
Beijing SL Pharmaceutical Co., Ltd. announced its profit results for the half year ended June 30, 2023 |
I see |
|
Beijing Shuangling Pharmaceutical obtained anti-cancer drug registration certificate |
mt. |
|
Beijing Shuangle Pharmaceutical Co., Ltd. approved the distribution of final cash dividend for 2022, and the payment date will be June 28, 2023 |
I see |
|
Beijing Erlu Pharmaceutical Co., Ltd. plans to distribute final cash dividend in 2022 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announced profit results for the first quarter ended March 31, 2023 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announced its full-year profit results as of December 31, 2022 |
I see |
|
Beijing SL Pharma registers diabetes drug |
mt. |
|
Beijing Shuanglu Pharmaceutical’s influenza drug receives marketing approval in China |
mt. |
|
Beijing Shuangshu Pharmaceutical’s Argatroban Injection Receives Regulatory Approval |
mt. |
|
Beijing Shuanglong Pharmaceutical Co., Ltd. agreed to transfer the remaining 30% equity of Xinxiang Shuanglong Pharmaceutical Co., Ltd. held by Xinxiang Chemical Fiber Co., Ltd. for 10.8 million yuan. |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announced profit results for the nine months ended September 30, 2022 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announced its profit results for the half year ended June 30, 2022 |
I see |
|
Beijing Shuangle Pharmaceutical Co., Ltd. has implemented the 2021 A-share final dividend, and the payment date will be June 29, 2022 |
I see |
|
Beijing Shuanglong Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 002038) withdraws from the Shenzhen Stock Exchange A-share component index |
I see |
|
Beijing Shuanglong Pharmaceutical Co., Ltd. (SZSE: 002038) fell out of the SZSE Component Index |
I see |
|
Beijing Shuangle Pharmaceutical Co., Ltd. approved cash dividends for 2021 |
I see |
|
Beijing Shuangle Pharmaceutical Co., Ltd. plans to distribute final cash dividend for 2021 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announces profit results for the first quarter ended March 31, 2022 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announces full-year profit results for the year ended December 31, 2021 |
I see |
|
Beijing SL Pharmaceutical Co., Ltd. announces profit results for the nine months ended September 30, 2021 |
I see |
|
Beijing Erlu Pharmaceutical Co., Ltd. announced its profit results for the half year ended June 30, 2021 |
I see |
|
Beijing Shuangle Pharmaceutical Co., Ltd. announced its 2020 cash dividend, with the payment date being July 7, 2021 |
I see |
More charts
Beijing SL Pharmaceutical Co., Ltd. specializes in the production and sales of genetically engineered drugs. Products are mainly used to treat neutropenia, thrombocytopenia, renal cancer, melanoma and chronic skin ulcers.
More information about the company
![consensus](https://www.marketscreener.com/images/consensus_flch.gif)
purchase
average price target
12:00CNY
Spread/average target
-15.31%
consensus
Annual profit – surprise rate